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Objective—To determine whether midtrimester insulin resistance (IR) is associated with
subsequent preeclampsia.
Study Design—This is a secondary analysis of 10,154 nulliparas administered vitamin C and E
or placebo daily from 9-16 weeks' gestation until delivery. Of these, 1,187 women had fasting
plasma glucose and insulin tested between 22 and 26 weeks' gestation. IR was calculated by the
homeostasis model assessment (HOMA-IR) and the quantitative insulin sensitivity check index
(QUICKI).
Results—Obese women were twice as likely to have a HOMA-IR ≥ 75th percentile. Hispanic
and African-American women had a higher percentage ≥ 75th percentile for HOMA-IR than
Caucasians (42.2, 27.2 and 16.9%, respectively, p<0.001). HOMA-IR ≥ 75th percentile was higher
among the 85 nulliparas who subsequently developed preeclampsia compared with women who
remained normotensive (40.5% vs. 24.8%; adjusted odds ratio 1.9, 95% confidence interval
[1.1-3.2]). QUICKI results were similar to HOMA-IR.
Conclusion—Midtrimester maternal IR is associated with subsequent preeclampsia.
Keywords
Insulin resistance; low risk nulliparas; risk for preeclampsia
Introduction
Insulin resistance (IR) was first proposed in 19361 and has been established to play a major
role in Type II diabetes mellitus and in the pathogenesis of hypertension, dyslipidemias, and
coronary artery disease. Virtually all obese women with hypertension have elevated insulin2
and the highest levels occur in obese women with excessive abdominal adipose tissue.3
Insulin resistance is a hallmark of obesity, and in pregnant women, obesity is a consistent
risk factor for preeclampsia.
Normal pregnancy is characterized by lower fasting, higher postprandial glucose values and
hyperinsulinemia. After an oral glucose meal, gravid women demonstrate both prolonged
hyperglycemia and hyperinsulinemia as well as greater suppression of glucagon.4 This
cannot be explained by a decreased metabolism of insulin because its half-life during
pregnancy is not changed.5 Instead, this response is consistent with a pregnancy-induced
state of peripheral insulin resistance, the purpose of which is likely to ensure a sustained
postprandial supply of glucose to the fetus. Indeed, insulin sensitivity in late normal
pregnancy is 45 to 70 percent lower than that of nonpregnant women.6-7
Our objective was to determine whether increased maternal midtrimester insulin resistance
is associated with subsequent preeclampsia. To test this hypothesis, we performed a
secondary analysis of a subgroup of low risk nulliparas from a multicenter, randomized trial
of daily vitamin C and E supplementation versus placebo for prevention of complications of
pregnancy-associated hypertension.8
Materials and Methods
This was a secondary analysis of the randomized trial in 10,154 nulliparas administered
vitamin C and E or placebo daily from 9-16 weeks' gestation until delivery conducted at the
16 clinical centers that were members of the Eunice Kennedy Shriver National Institute of
Child Health and Human Developmental Maternal-Fetal Medicine Units Network between
2003 and 2008. Full details of the study design and technique of data collection have been
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previously described.8 Women included in the trial had blood samples collected at
randomization, 24 and 32 weeks' gestation, and at admission for delivery. Information was
collected as to whether the women fasted for 12 hours or more even though they were not
specifically instructed to fast for any of these visits. Women were included in this secondary
analysis if they had a blood sample collected between 22-26 weeks' gestation and had fasted
for 12 hours or more prior to the blood collection. The study was approved by the
Institutional Review Boards of each clinical site and the data coordinating center.
The diagnosis of hypertension was based on blood-pressure measurements obtained during
or after the 20th week of pregnancy, excluding intraoperative blood pressures and
intrapartum systolic pressures. Severe pregnancy-associated hypertension was defined as a
systolic pressure of 160 mmHg or more or a diastolic pressure of 110 mmHg or more on two
occasions 2 to 240 hours apart, or a single blood-pressure measurement that was severely
elevated and that led to treatment with an antihypertensive medication. Mild pregnancy-
associated hypertension was defined as a systolic pressure between 140 and 159 mmHg or a
diastolic pressure between 90 mmHg and 109 mmHg on two occasions 2 to 240 hours apart.
Mild preeclampsia was defined as mild pregnancy-associated hypertension with
documentation of proteinuria within 72 hours before or after an elevated blood-pressure
measurement. Proteinuria was defined as total protein excretion of 300 mg or more in a 24-
hour urine sample or 2+ or higher on dipstick testing, or a protein-to-creatinine ratio of 0.35
or more if a 24-hour urine sample was not available. Severe preeclampsia was defined as
preeclampsia with either severe pregnancy-associated hypertension or protein excretion of 5
g or more in a 24-hour urine sample or as mild pregnancy-associated hypertension with
oliguria (<500 ml in a 24-hour urine sample), pulmonary edema (confirmed by
radiography), or thrombocytopenia (platelet count of <100,000 per cubic millimeter).
Preeclampsia included mild and severe preeclampsia, HELLP syndrome and eclampsia. To
determine the diagnosis of preeclampsia, deidentified medical charts of all women with
pregnancy-associated hypertension were reviewed centrally by at least three reviewers.
Determination of Insulin Resistance
Insulin resistance was calculated from fasting maternal plasma glucose and insulin
concentrations obtained between 22 and 26 weeks' gestation. Insulin resistance was
calculated using the surrogate indices of homeostasis model assessment (HOMA) and also
the quantitative insulin sensitivity check index (QUICKI).9-10 Surrogate indirect indices
describe glucose-insulin homeostasis by empiric non-linear equations. The intent of the
empiric equations is to accommodate glucose ranges, assure reduced suppression of hepatic
glucose production and to allow the use of total insulin assays. The equations for the indirect
indices are:
The surrogate indices impute a dynamic ∃-cell function (insulin as stimulated by maternal
glucose) from fasting steady state data.11
Insulin and glucose assays were performed at the Metabolism Core Laboratory at the
University of Alabama at Birmingham. Glucose was measured on the Stanbio Sirrus, an
automated spectrophotometric chemistry analyzer using a glucose-oxidase methodology.
The intra-assay coefficient of variation (CV) was 1.21% and the inter-assay CV was
3.065%. Insulin was measured on the TOSOH AIA-600 II analyzer which uses a
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chemiluminescence technology. Insulin was measured using a two-site immunoenzymatic
assay. The intra-assay CV was 4.42% and the inter-assay CV was 1.49%.
Statistical Analysis
Insulin resistance was evaluated across body mass index categories using the Cochran-
Armitage test for trend. Other categorical variables were compared using the chi-square test.
Percentiles for each week of gestation were determined for insulin, glucose, HOMA-IR and
QUICKI using the data from the normotensive, non-proteinuric women from this cohort. For
each marker (insulin, glucose, HOMA-IR, QUICKI), the Breslow-Day test for homogeneity
was used to determine if there was a difference in the effect of body mass index among
women who were Hispanic, African American, or Caucasian or other. Multivariable logistic
regression analysis was used to calculate odds ratios and included race or ethnic group, body
mass index and blood pressure at study entry (9-16 weeks gestational age), treatment group
(vitamins, placebo) and gestational age at sampling. For all statistical tests, a nominal p
value less than 0.05 was considered to indicate statistical significance; no adjustments were
made for multiple comparisons. Analyses were performed using SAS software (Cary, NC).
Results
A total of 10,154 women were randomized in the parent trial, and outcome data were
available for 9,969 women. While 68% of these women had a study sample available
between 22-26 weeks' gestation, only 1,187 (12%) women had a 12 hour or more fasting
sample available for analysis. Population characteristics of women with and without fasting
samples are detailed in Table 1. Body mass index (BMI) was measured at study entry (9-16
weeks' gestation). Fasting samples were available in 14.2% of Caucasians, 10.3% of African
Americans and 10.0% of Hispanics. While there were statistically significant differences in
maternal age, education level and diastolic blood pressure, these differences were small and
not clinically meaningful. Of the 1,187 women included in this secondary analysis, 22%
were African-American, 26% Hispanic and 52% Caucasian or other. Fifty-two percent were
under or normal weight and 48% were overweight or obese.
Insulin and glucose levels did not differ by whether women were in the vitamin or placebo
treated group. The 75th percentile for insulin, glucose and HOMA-IR and the 25th percentile
for QUICKI were chosen after other cutoffs were considered and the greatest significance
was achieved with these percentiles. The frequency of glucose, insulin, and HOMA-IR at or
above the 75th percentile and QUICKI less than the 25th percentile significantly increased
with increasing body mass index (trend p<0.0001). At midtrimester, obese women were
approximately two times more likely than normal weight women to have a fasting glucose,
insulin, and HOMA-IR at or above the 75th percentile and QUICKI less than the 25th
percentile (Table 2).
Hispanic women had a higher percentage of glucose, insulin and HOMA-IR at or above the
75th percentile and QUICKI less than the 25th percentile compared with African-Americans
and Caucasians (p<0.001, Table 3). Compared with Caucasian women, African-American
women had a higher percentage of insulin and HOMA-IR at or above the 75th percentile and
QUICKI less than the 25th percentile (p<0.001, Table 3) but not glucose at or above the 75th
percentile (p=0.86, Table 3). There was a significant interaction between race and BMI
(under/normal weight, overweight/obese) for glucose, insulin and HOMA-IR at or above the
75th percentile and QUICKI less than the 25th percentile. Among the 568 overweight or
obese women, 48% of Hispanics, 34% of African-Americans and 28% of Caucasians had a
HOMA-IR at or above the 75th percentile.
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As expected, the 44 women (3.7%) in the cohort with gestational diabetes mellitus were
significantly more likely to have a glucose and HOMA-IR at or above the 75th percentile
and QUICKI less than the 25th percentile than women without gestational diabetes (glucose:
59% vs. 26%, p<.0001; HOMA-IR: 43% vs. 25%, p=0.007; QUICKI 43% vs. 25%,
p=0.007). While the gestational diabetic women were more likely to have an insulin level at
or above the 75th percentile compared with non-diabetic women, this was not statistically
significant (39% vs. 25%, p=0.05).
In the overall cohort, 85 women developed preeclampsia, 592 remained normotensive and
non-proteinuric, and 510 had an elevated blood pressure or proteinuria but not preeclampsia.
Only 8 of the 85 women who developed preeclampsia had gestational diabetes mellitus.
Fasting maternal glucose, insulin, and HOMA-IR at or above the 75th percentile and
QUICKI less than the 25th percentile were significantly more likely among those who
subsequently developed preeclampsia compared with women who remained normotensive
and non-proteinuric (p<0.05, Table 4). A HOMA-IR at or above the 75th percentile had a
sensitivity of 40% and specificity of 75% for subsequent preeclampsia with a positive
predictive value of 19% and a negative predictive value of 90%. (Values for the QUICKI
analyses were identical to the HOMA-IR.) Multivariable analyses confirmed midtrimester
fasting insulin, HOMA-IR at or above the 75th percentile and QUICKI less than the 25th
percentile to be significantly associated with preeclampsia as compared to women with no
hypertension or proteinuria (Table 4). The 510 women with an elevated blood pressure or
proteinuria were similar to the normotensive, non-proteinuric women in regard to a HOMA-
IR greater or equal 75th percentile or QUICKI less than the 25th percentile (24% vs 25%,
p=0.8).
Comment
After controlling for body mass index, race, ethnicity, treatment group, enrollment blood
pressure and gestational age at sampling, midtrimester fasting HOMA-IR at or above the
75th percentile and QUICKI less than the 25th percentile remain a significant risk factor for
subsequent preeclampsia. In low risk nulliparas increasing BMI or Hispanic/African-
American ethnicity/race were significantly associated with HOMA-IR at or above the 75th
percentile and QUICKI less than the 25th percentile between 22 and 26 weeks' gestation.
Insulin resistance describes a decreased sensitivity to insulin in regard to glucose disposal
and to inhibition of hepatic glucose production. The gold standard for direct testing of
insulin resistance is by euglycemic glucose clamp testing.12 Direct testing is time
consuming, labor intense, expensive, requires an experienced operator and it is not feasible
for epidemiologic studies, large clinical trials or for routine clinical use. We used two
indirect surrogates in this analysis, the homeostasis model assessment (HOMA-IR) and
quantitative insulin sensitivity check index (QUICKI) methods. These indirect indices are
dependent on a required fasting basal state (12 or more hours), glucose in the normal range,
and the assumption that insulin levels are stable and that hepatic glucose production is
constant. Glucose homeostasis is a feedback loop involving hepatic glucose production and
insulin secretion from beta cells.9 HOMA-IR and QUICKI describe the glucose-insulin
homeostasis loop by empiric non-linear equations. They accommodate glucose ranges,
assure reduced suppression of hepatic glucose production, allow the use of total insulin
assays, and impute a dynamic beta cell function (insulin stimulated by glucose) from fasting
steady-state data.10-11 In nonpregnant women, HOMA-IR and QUICKI have a reasonable
linear correlation with direct evaluation using the glucose clamp to assess insulin sensitivity/
resistance.11,13-14 We are not aware of any reports comparing the glucose clamp to the
HOMA-IR or QUICKI methodology in pregnant women.
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The use of indirect indices of insulin resistance may not be generalizable from a single
testing facility due to the lack of a standardized insulin assay.15-18 Thus, cutoff points for IR
require development of the 75th percentile HOMA-IR and the 25th percentile for QUICKI at
each testing facility. It is also important to note that population differences may have an
effect on the utility of surrogate indices to reflect insulin resistance. Alvarez and colleagues
found that surrogate indices may be more accurate in African-American versus white
Americans and more accurate in overweight versus normal weight adults.19
Parretti and colleagues20 assessed insulin sensitivity in 829 gravidas at 16 to 20 and at 26 to
30 weeks' gestation. Their HOMA-IR and QUICKI insulin sensitivity analysis results were
similar and at 16-20 weeks gestation had a sensitivity of 79-85% to predict subsequent
preeclampsia with a specificity of 97% for both analyses. Our data confirms a significant
relationship with a HOMA-IR at or above the 75th percentile and QUICKI less than the 25th
percentile at 22 to 26 weeks' gestation with subsequent preeclampsia although with a lower
sensitivity of 40% and specificity of 75%. The higher sensitivity and specificity of the
Parretti report may relate to their more homogeneous population (Italians of white race),
their exclusion of women with gestational diabetes mellitus, their selection of women with a
body mass index of between 19 and 25 kg/m2 or to their method of calculation of the 75 to
100 percentile (HOMA-IR) or the 0 to 25 percentile (QUICKI) quartiles. In our report, race,
ethnicity, and maternal weight significantly increased the percent of women whose HOMA-
IR was at or above the 75th percentile and whose QUICKI was less than the 25th percentile.
Sierra-Laguado and associates21 have also reported that midtrimester log-HOMA analysis
was significantly associated with subsequent preeclampsia. Within their cohort of 572
normotensive pregnant women at a gestational age of less than 30 weeks the 18 women who
developed preeclampsia had a higher log-HOMA than 72 controls matched by body mass
index, gestational and maternal age at enrollment.
Roberts and Gammill22 have emphasized the importance of controlling for maternal weight
and for insulin resistance testing prior to the clinical appearance of preeclampsia. Parretti et
al.20 enrolled lean gravidas and Sierra-Laguado et al21 matched for maternal weight.
Gravidas in both reports were assessed early in pregnancy prior to clinically evident
preeclampsia. We also determined fasting glucose and insulin concentrations prior to
clinically evident preeclampsia (22 to 26 weeks' gestation) and our analyses controlled for
maternal weight and other potential risk factors for preeclampsia. Roberts and Gammill22
concluded that even if the midtrimester HOMA-IR is only 20% predictive of subsequent
preeclampsia that it would be similar to the “gold standard” of uterine artery Doppler, also
20%, and which entails more complex and costly assessment of risk.23
In summary, maternal midtrimester insulin resistance increased significantly (HOMA-IR at
or beyond the 75th percentile or QUICKI less than the 25th percentile) with increasing body
mass index and among Hispanic and African-American women. Midtrimester maternal IR is
associated with a significantly increased risk of subsequent preeclampsia.
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Figure 1. Enrollment, randomization, and follow-up of participants
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Table 1
Population Characteristics of Women with and Without Fasting Insulin and Glucose
Measured Between 22-26 Weeks Gestation *
Characteristic Women with fasting samples
N=1,187
Women without fasting samples
N=8,782
p-value
Maternal age (years) 23.6 ± 4.9 23.5 ± 5.3 0.03
Gestational age at study entry (weeks) 12.3 ± 1.8 13.5 ± 2.1 <0.01
Race <0.01
 Hispanic 307 (25.9) 2,776 (31.6)
 African American 260 (21.9) 2,258 (25.7)
 Caucasian / Other 620 (52.2) 3,748 (42.7)
BMI at study entry # 0.13
 <18.5 (underweight) 39 (3.3) 235 (2.7)
 18.5-24.9 (normal) 580 (48.9) 4,325 (49.3)
 25.0-29.9 (overweight) 286 (24.1) 2,335 (26.6)
 30.0-39.9 (obese) 228 (19.2) 1,561 (17.8)
 ≥ 40.0 (morbidly obese) 54 (4.5) 323 (3.7)
Treatment group 0.40
 Vitamins 581 (48.9) 4,412 (50.2)
 Placebo 606 (51.1) 4,370 (49.8)
Previous pregnancy < 20 weeks 296 (24.9) 1,991 (22.7) 0.08
Smoked during pregnancy 202 (17.0) 1,349 (15.4) 0.14
Education level (years) 13.0 ±2.6 12.8 ± 2.7 <0.01
Blood pressure at study entry
 Systolic 109 ± 10 109 ± 10 0.35
 Diastolic 66 ± 8 65 ± 8 0.04
*
Plus-minus values are means ± SD.
#
Study entry was 9-16 weeks' gestation
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Table 4
Midgestation fasting glucose, insulin, and insulin resistance (HOMA-IR and QUICKI) and subsequent
preeclampsia.
Measure Preeclampsia (%) N=85 Normal (%) N=592 OR (95% CI) Adjusted OR (95% CI)*
Glucose ≥ 75th %ile 37.6 26.5 1.7 [1.0-2.7] 1.5 [0.9-2.5]
Insulin ≥ 75th %ile 40.5 25.3 2.0 [1.3-3.2] 1.8 [1.0-3.1]
HOMA-IR ≥ 75th %ile 40.5 24.8 2.1 [1.3-3.3] 1.9 [1.1-3.2]
QUICKI < 25th %ile 40.5 25.0 2.0 [1.3-3.3] 1.9 [1.1-3.2]
*
Adjusted for race or ethnic group, body mass index and blood pressure at study entry, treatment group, and gestational age at sampling.
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